Percorrer por autor "Vitorino, Carla"
A mostrar 1 - 4 de 4
Resultados por página
Opções de ordenação
- Amorphous nasal powder advanced performance : in vitro/ex vivo studies and correlation with in vivo pharmacokineticsPublication . Henriques, Patrícia; Bicker, Joana; Carona, Andreia; Miranda, Margarida; Vitorino, Carla; Doktorovová , Slavomíra; Fortuna, AnaPurpose: Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to increase drug release performance, while using polymers with mucoadhesive properties. The aim of the present study was to apply this solubility enhancement technique to a poorly soluble drug for nasal delivery, while comparing two particle engineering strategies, namely spray dried microparticles and chimeral agglomerates, with the corresponding physical blends with crystalline drug. Methods: Formulations of piroxicam were manufactured using varied polymer and particle engineering strategies and evaluated through in vitro drug release and ex vivo permeation studies, as well as nasal deposition and in vivo pharmacokinetic studies. Results: ASD with hydroxypropyl methylcellulose (HPMC) showed enhanced drug release and permeation, compared to polyvinylpyrrolidone/vinyl acetate formulations and blends. Nasal deposition of HPMC chimeral agglomerates suggested off-target deposition. In vivo pharmacokinetic studies revealed that spray-dried HPMC-containing microparticles exhibited the highest maximum plasma concentration (Cmax) and the lowest time to attain it (tmax). In vitro release rate and in vivo absorption rate were correlated as well as tmax and in vitro performance. When excluding the formulation with least nasal targeted deposition, in vitro release and ex vivo permeation performance were also correlated with Cmax and area under the drug concentration-time curve (AUC) from 0 to 1 h, with R2 > 0.89. Conclusion: ASD for nasal delivery provide fast drug absorption, which depends on the supersaturation ability of the polymer employed. In vitro-in vivo correlations suggested that in vitro release and ex vivo permeation studies are predictive tools regarding nasal absorption.
- Composite Films of Nanofibrillated Cellulose with Sepiolite: Effect of Preparation StrategyPublication . Alves, Luis; Ramos, Ana; Rasteiro, Maria G.; Vitorino, Carla; Ferraz, Eduardo; Ferreira, Paulo J. T.; Puertas, Maria L.; Gamelas, José A. F.Cellulose nanofibrils (CNFs) are nanomaterials with promising properties to be used in food packaging and printed electronics, thus being logical substitutes to petroleum-based polymers, specifically plastics. CNFs can be combined with other materials, such as clay minerals, to form composites, which are environmentally friendly materials, with acceptable costs and without compromising the final properties of the composite material. To produce composite films, two strategies can be used: solvent casting and filtration followed by hot pressing. The first approach is the simplest way to produce films, but the obtained films may present some limitations. In the present work, CNFs produced using enzymatic or TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl radical) oxidation pretreatments, followed by high-pressure homogenization, or only by mechanical treatment (homogenization), were used to produce films by both the available procedures. The films obtained by filtration + hot pressing presented higher tensile strength and Young’s modulus compared with those obtained by solvent casting. In general, a decrease in the values of these mechanical properties of the films and a decrease in elongation at break, with the addition of sepiolite, were also observed. However, for the TEMPO CNF-based films, an improvement in tensile strength could be observed for 10% of the sepiolite content. Furthermore, the time necessary to produce films was largely reduced by employing the filtration procedure. Finally, the water vapour barrier properties of the films obtained by filtration are comparable to the literature values of net CNF films. Thus, this technique demonstrates to be the most suitable to produce CNF-based composite films in a fast way and with improved mechanical properties and suitable gas barrier properties.
- Drilling down the bioequivalence assessment of topical antifungal products : microstructure and releasePublication . Miranda, Margarida; Cardoso, Catarina; Pais, Alberto A.C.C.; Brown, Marc; Vitorino, CarlaIn recent years, the regulatory mechanisms for topical generic product bioequivalence (BE) assessment have been subjected to noteworthy changes, with the FDA issuing product specific guidances, and the EMA adopting a more universal approach with the quality and equivalence of topical products draft guideline. The agencies advise on a modular strategy for BE documentation. Nevertheless, their scope, data analysis and criteria are rather distinct. This study aims to tackle bioequivalence assessment issues of complex topical formulations starting by statistical implications of the EMA/FDA approaches concerning the documentation of qualitative (Q1), quantitative (Q2), microstructure (Q3) and performance requirements (Q4). As a model drug product, a bifonazole 10 mg/g cream formulation was selected. For this specific formulation, the commercially available Reference Product (RP) was compared with two comparator products, also commercially available, referred to as comparator product A (CPA) and comparator product B (CPB). The former displays Q1 sameness and Q2 differences, whilst CPB is categorically considered as Q1/Q2 different. Furthermore, intending to establish a regulatory rationale for the submission of a generic product according to the updated regulatory requirements, the RP was likewise compared with a Test Product (TP). This formulation was designed to display equal Q1/Q2 profile to that of the RP. Validated rheology and in vitro release test (IVRT) methods were used to infer on Q3/Q4 characteristics. During rheology studies, statistically significant RP batch to batch differences were observed. Therefore, in an attempt to surpass this heterogeneity, the initial pool of RP batches was expanded to include RP product batches at different lifecycle stages. Despite this effort, it was not possible to classify the RP/TP, RP/CPA or RP/CPB as rheologically equivalent products. Nevertheless, product performance results, retrieved from IVRT, were able to sustain equivalence between the RP and the formulations exhibiting Q1 sameness (TP and CPA). It should however be mentioned, that for some RP batch combinations, the IVRT results failed to demonstrate equivalence according to the EMA requirements. Enlarging the RP batch pool was then a critical step in further understanding an optimum statistical approach for establishing equivalence in product performance. This study highlights the need to that a ‘one-fits-all approach’ may not be an optimum path way for establishing the regulatory strategy and requirements to support generic product bioequivalence.
- In vitro studies into establishing therapeutic bioequivalence of complex topical products : weight of evidencePublication . Miranda, Margarida; Volmer, Zoe; Cornick, Alicia; Goody, Aidan; Cardoso, Catarina; Pais, Alberto A.C.C.; Brown, Marc; Vitorino, CarlaOver the past decade, topically applied drug products have experienced extraordinary price increases, due to the shortage of multisource generic drug products. This occurrence is mainly related to the underlying challenges evolved in topical bioequivalence documentation. Although there has been continuing regulatory efforts to present surrogate in vitro methods to clinical endpoint studies, there is still a continued need for cost- and time-efficient alternatives that account for product specificities. Hence, this work intended to expose bioequivalence assessment issues for complex topical formulations, and more specifically those related with product efficacy guidance. As a model drug and product, a bifonazole 10 mg/g cream formulation was selected and two different batches of the commercially available Reference Product (RP) were used: RP1 that displayed lower viscosity and RP4 which presented high, but not the highest, viscosity. In vitro human skin permeation testing (IVPT) was carried out and the results were evaluated by means of the traditional bioequivalence assessment approach proposed by the EMA, as well as by the Scaled Average Bioequivalence assessment approach proposed by the FDA. Based on previous experience, there was an expectation of a high level of variability in the results, thus alternative methods to evaluate local drug skin availability were developed. More specifically, an infected skin disease model, where ex vivo human skin was infected and ATP levels were used as a biological marker for monitoring antifungal activity after product application. The results showed that permeation equivalence could not be supported between the different RP batches. In contrast, this statistical difference between the formulation batches was not indicated in the disease model. Nevertheless, in pivotal IVPT studies, the lowest permeant formulation (RP4) evidenced a higher antifungal in vitro activity as reported by the lower levels of ATP. A critical appraisal of the results is likewise presented, focusing on an outlook of the real applicability of the regulatory guidances on this subject.